FDA says Novartis withheld data problem before drug approval

U.S. regulators want to know why Novartis didnt disclose a problem with testing data until after the Swiss drugmakers $2.1 million gene therapy was approved. The Food and Drug Administration said on Tuesday that the manipulated data involved testing in animals, not patients, and its confident that the drug, called Zolgensma, should remain on the market. The agency said its investigating and will consider criminal or civil penalties if appropriate. Zolgensma was approved in May for children under 2, becoming the most expensive treatment ever. Its a one-time treatment for a rare inherited condition, spinal muscular atrophy, which destroys a babys muscle control.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.008971 seconds